FAGR Fagron SA

Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l.

Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l.

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2022 – 7:30AM CET

Disclosure of notifications received from Active Ownership Corporation S.à r.l. and from AOC Pharma S.à r.l.

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received notifications from Active Ownership Corporation S.à r.l. and AOC Pharma S.à r.l.

Notification Active Ownership Corporation S.à r.l.

  • On 15 December 2022, Fagron received a notification that the shareholding of Active Ownership Corporation S.à r.l. crossed the disclosure threshold of 3% on 12 December 2022 as the result of the disposal of voting securities or voting rights and the downward crossing of the lowest disclosure threshold.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 12 December 2022, Active Ownership Corporation S.à r.l. held a total of 0 voting rights.
  • Based on the denominator of 72,992,654 (total number of voting rights), Active Ownership Corporation S.à r.l. held 0% of the total number of voting rights on 12 December 2022.
  • Active Ownership Corporation S.à r.l. is jointly controlled by two shareholders, Active Ownership Advisors GmbH and Active Ownership Investments Ltd. Active Ownership Advisors GmbH is controlled by Florian Schuhbauer. Active Ownership Investments Ltd. is controlled by Active Ownership LP, which is controlled by Active Ownership Management Ltd, which is controlled by Klaus Röhrig.
  • On 1 October 2019, an agreement was concluded by Active Ownership Fund SICAV-FIS SCS regarding the appointment of Active Ownership Corporation S.à r.l. as AIFM (alternative investment fund manager) for Active Ownership Fund SICAV-FIS SCS. Pursuant to this agreement and appointment Active Ownership Corporation S.à r.l will exercise the voting rights with respect to shares held by Active Ownership Fund SICAV-FIS SCS.
  • Active Ownership Corporation S.à r.l. is an alternative investment fund manager, which can exercise the voting rights at its discretion in the absence of specific instructions.
  • The notification of Active Ownership Corporation S.à r.l. can be viewed via this .

Notification AOC Pharma S.à r.l.

  • On 15 December 2022, Fagron received a notification that the shareholding of AOC Pharma S.à r.l. crossed the disclosure threshold of 5% on 12 December 2022 as the result of the acquisition of voting securities or voting rights.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 12 December 2022, AOC Pharma S.à r.l. held a total of 6,377,392 voting rights.
  • Based on the denominator of 72,992,654 (total number of voting rights), AOC Pharma S.à r.l. held 8.74% of the total number of voting rights on 12 December 2022.
  • AOC Pharma S.à r.l. is controlled by Active Ownership Fund SICAV-FIS SCS. Active Ownership Capital S.à r.l. is the general partner of Active Ownership Fund SICAV-FIS SCS. On 1 October 2019, an agreement was concluded by Active Ownership Fund SICAV-FIS SCS regarding the appointment of Active Ownership Corporation S.à r.l. as AIFM (alternative investment fund manager) for Active Ownership Fund SICAV-FIS SCS. Pursuant to this agreement and appointment Active Ownership Corporation S.à r.l will exercise the voting rights with respect to shares held by Active Ownership Fund SICAV-FIS SCS. Active Ownership Corporation S.à r.l. and Active Ownership Capital S.à r.l. are both jointly controlled by two shareholders, Active Ownership Advisors GmbH and Active Ownership Investments Ltd. Active Ownership Advisors GmbH is controlled by Florian Schuhbauer. Active Ownership Investments Ltd. is controlled by Active Ownership LP, which is controlled by Active Ownership Management Ltd, which is controlled by Klaus Röhrig.
  • The notification of Active Ownership Corporation S.à r.l. can be viewed via this .

Further information

Karen Berg

Global Investor Relations Manager

Tel. 99

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:



EN
19/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: 3Q25 preview - USD headwind to take centre stage. Basic-Fit: 3Q25 results preview, new consensus, we expect strong membership ingrowth. Fagron: 3Q25 growth hiccup in N America, strong organic performance in EMEA, Latam. Lotus Bakeries: UK VAT conflict for Näkd negatively impacts 2024 profitability. Ontex: 3Q25 preview: consensus implies a second profit warning for FY25F. Randstad: Preview 3Q25F results due 22 October; consensus released. Staffing: French revenue impro...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Thibault Leneeuw
  • Wim Lewi
 PRESS RELEASE

Fagron reports solid third quarter performance with 6.4% revenue growt...

Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 October 2025 – 7:00 AM CET Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2025. Key Highlights Q3 2025 organic growth at CER1 of 8.5% on a normalized basis2 and 5.7% including the GLP-1 impactRevenue for ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch